Subtype
Malignant Reproductive System Neoplasm
CI-CAN-00001172Explore in graph →
2,803 active trials38 approved drugs186 evidence items
- NCIt
- C36076
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001172Explore in graph →
Clinical trials
12,155 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,473)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01704027 | Safety Study of Pelvic and Prostatic SIB-IMRT With Long-term Androgen Deprivation for High Risk Localized Prostate Cancer | terminated | Phase 2 | 28 | Centre Georges Francois LeclercOTHER | 1 | Sep 18, 2014 | clinicaltrials |
| NCT01786226 | Mifepristone to Treat Uterine Fibroids | terminated | Phase 2 / Phase 3 | 220 | Mediterranea Medica S. L.OTHER | 1 | Sep 5, 2014 | clinicaltrials |
| NCT00958893 |
| An Extension Study Evaluating Safety and Efficacy of Proellex® In Women Who Have Previously Completed ZPU 003 Ext |
| terminated |
| Phase 2 |
| 4 |
| Repros Therapeutics Inc.INDUSTRY |
| 1 |
| Aug 25, 2014 |
| clinicaltrials |
| NCT00470067 | Doxorubicin Hydrochloride Liposome and Carboplatin in Treating Patients With Recurrent, Stage III, or Stage IV Primary Endometrial Cancer | terminated | Phase 2 | 9 | Roswell Park Cancer InstituteOTHER | 1 | Aug 22, 2014 | clinicaltrials |
| NCT00683917 | Pharmacokinetics, Safety and Efficacy Study of Proellex in Pre-menopausal Women With Symptomatic Uterine Fibroids | terminated | Phase 2 | 10 | Repros Therapeutics Inc.INDUSTRY | 2 | Aug 21, 2014 | clinicaltrials |
| NCT00385827 | A Safety and Efficacy Study of Siltuximab (CNTO 328) in Male Subjects With Metastatic Hormone-Refractory Prostate Cancer (HRPC) | terminated | Phase 2 | 106 | Centocor, Inc.INDUSTRY | 7 | Aug 20, 2014 | clinicaltrials |
| NCT00004050 | Leuvectin Followed By Surgery in Treating Patients With Stage II or Stage III Prostate Cancer | terminated | Phase 2 | 13 | VicalINDUSTRY | 1 | Jul 29, 2014 | clinicaltrials |
| NCT00005072 | Leuvectin in Treating Patients With Locally Recurrent Prostate Cancer | terminated | Phase 1 / Phase 2 | 25 | VicalINDUSTRY | 1 | Jul 29, 2014 | clinicaltrials |
| NCT00626561 | Bevacizumab and Paclitaxel for Neuroendocrine Tumors of the Cervix | terminated | Phase 2 | 4 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 7, 2014 | clinicaltrials |
| NCT00418093 | Oxaliplatin, Gemcitabine and Bevacizumab in Women With Recurrent Mullerian Carcinoma | terminated | Phase 2 | 19 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 19, 2014 | clinicaltrials |
| NCT00515112 | Testosterone Replacement in Men With Non-Metastatic Castrate Resistant Prostate Cancer | terminated | Phase 2 | 6 | University of ChicagoOTHER | 1 | Jun 11, 2014 | clinicaltrials |
| NCT00089076 | MDX-010 in Treating Patients With Recurrent or Refractory Lymphoma | terminated | Phase 1 / Phase 2 | 18 | National Cancer Institute (NCI)NIH | 1 | May 30, 2014 | clinicaltrials |
| NCT01483586 | Safety and Efficacy of Kanglaite Gelcaps in Prostate Cancer | terminated | Phase 2 | 90 | KangLaiTe USAINDUSTRY | 1 | Apr 14, 2014 | clinicaltrials |
| NCT00678015 | Pharmacokinetic and Efficacy Study of Nordihydroguaiaretic Acid (NDGA) in Non Metastatic Recurrent Prostate Cancer | terminated | Phase 2 | 12 | University of California, San FranciscoOTHER | 1 | Apr 9, 2014 | clinicaltrials |
| NCT00887640 | Impact of Temsirolimus Therapy on Circulating Tumor Cell Biology In Men With Castration Resistant Metastatic Prostate Cancer | terminated | Phase 2 | 11 | Duke UniversityOTHER | 1 | Feb 26, 2014 | clinicaltrials |
| NCT01176513 | GE-148-002: A Phase 2, Open-label, Single-Center Study to Assess GE-148 (18F) Injection PET Imaging to Detect Localized Prostate Cancer | terminated | Phase 2 | 25 | GE HealthcareINDUSTRY | 1 | Feb 14, 2014 | clinicaltrials |
| NCT00479635 | A Phase II Trial of TPI 287 in Patients With Metastatic Prostate Cancer | terminated | Phase 2 | 26 | Cortice Biosciences, Inc.INDUSTRY | 1 | Jan 22, 2014 | clinicaltrials |
| NCT01000948 | A Safety Study of ZD4054 in Prior Chemotherapy Treated Patients With Metastatic Hormone-resistant Prostate Cancer(DAPROCA-1) | terminated | Phase 2 | 24 | Aarhus University HospitalOTHER | 1 | Jan 8, 2014 | clinicaltrials |
| NCT00917865 | FACBC Positron Emission Tomography/Computed Tomography(PET/CT) Used in the Diagnosis of Primary Prostate Cancer | terminated | Phase 2 | 11 | David M. Schuster, MDOTHER | 1 | Jan 7, 2014 | clinicaltrials |
| NCT00510224 | Sandostatin for Patients With Androgen Independent Prostate Cancer | terminated | Phase 2 | 13 | University of California, San FranciscoOTHER | 1 | Dec 11, 2013 | clinicaltrials |
| NCT00138151 | Isotretinoin, Interferon Alpha-2b, and Paclitaxel in Stage IV, Recurrent, or Persistent Cervical Cancer | terminated | Phase 2 | 33 | University of Medicine and Dentistry of New JerseyOTHER | 1 | Nov 20, 2013 | clinicaltrials |
| NCT00945477 | Pazopanib as Second Line Therapy in Patients With Metastatic Prostate Cancer Refractory to Total Androgen Blockade | terminated | Phase 2 | 11 | Illinois CancerCare, P.C.OTHER | 1 | Nov 18, 2013 | clinicaltrials |
| NCT00053833 | S0025 Irinotecan in Treating Patients With Refractory Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer | terminated | Phase 2 | 2 | SWOG Cancer Research NetworkNETWORK | 2 | Nov 8, 2013 | clinicaltrials |
| NCT00814892 | Vaccine Therapy in Treating Patients With Non-Metastatic Prostate Cancer | terminated | Phase 2 | 2 | Mayo ClinicOTHER | 1 | Nov 5, 2013 | clinicaltrials |
| NCT01821859 | Abraxane/Bevacizumab | terminated | Phase 2 | 5 | OHSU Knight Cancer InstituteOTHER | 1 | Jul 26, 2013 | clinicaltrials |
| NCT00748527 | Carboplatin With or Without Decitabine in Treating Patients With Progressive, Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | terminated | Phase 2 | 134 | Cancer Research UKOTHER | 1 | Jul 10, 2013 | clinicaltrials |
| NCT00084448 | Paclitaxel and Celecoxib in Treating Patients With Recurrent or Persistent Platinum-Resistant Ovarian Epithelial or Primary Peritoneal Cancer | terminated | Phase 2 | — | Gynecologic Oncology GroupNETWORK | 1 | Jul 9, 2013 | clinicaltrials |
| NCT00002478 | Etoposide in Treating Patients With Advanced Ovarian or Cervical Cancer | terminated | Phase 2 | — | Gynecologic Oncology GroupNETWORK | 1 | Jun 10, 2013 | clinicaltrials |
| NCT00003179 | Surgery Plus Medroxyprogesterone in Preventing Endometrial Cancer | terminated | Phase 2 | 360 | Gynecologic Oncology GroupNETWORK | 2 | Jun 10, 2013 | clinicaltrials |
| NCT00583622 | Bevacizumab Plus Gemcitabine, Docetaxel, Melphalan, and Carboplatin in Ovarian Cancer Patients | terminated | Phase 2 | 13 | M.D. Anderson Cancer CenterOTHER | 1 | May 21, 2013 | clinicaltrials |
| NCT01383408 | Distinction Between Lung Cancer and Gynecological Cancers by Canine Scent Detection | terminated | Phase 2 | 752 | Schillerhoehe HospitalOTHER | 1 | May 7, 2013 | clinicaltrials |
| NCT00003386 | Vaccine Therapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer | terminated | Phase 2 | — | Gynecologic Oncology GroupNETWORK | 2 | Apr 11, 2013 | clinicaltrials |
| NCT00003624 | Amifostine in Treating Women With Ovarian, Peritoneal, Cervical, Fallopian Tube, Uterine, or Endometrial Cancer | terminated | Phase 2 | — | Gynecologic Oncology GroupNETWORK | 1 | Apr 11, 2013 | clinicaltrials |
| NCT00004037 | Docetaxel in Treating Patients With Recurrent or Refractory Ovarian or Primary Peritoneal Cancer | terminated | Phase 2 | — | Gynecologic Oncology GroupNETWORK | 2 | Apr 11, 2013 | clinicaltrials |
| NCT00006224 | Gemcitabine in Treating Patients With Persistent or Recurrent Cancer of the Cervix | terminated | Phase 2 | — | Gynecologic Oncology GroupNETWORK | 2 | Apr 11, 2013 | clinicaltrials |
| NCT00006482 | Gemcitabine and Cisplatin in Treating Patients With Refractory or Recurrent Cancer of the Cervix | terminated | Phase 2 | — | Gynecologic Oncology GroupNETWORK | 2 | Apr 11, 2013 | clinicaltrials |
| NCT00006812 | Capecitabine in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cavity Cancer | terminated | Phase 2 | — | Gynecologic Oncology GroupNETWORK | 2 | Apr 11, 2013 | clinicaltrials |
| NCT00023907 | Paclitaxel in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer | terminated | Phase 2 | — | Gynecologic Oncology GroupNETWORK | 1 | Apr 11, 2013 | clinicaltrials |
| NCT00030472 | Liposomal Doxorubicin in Treating Patients With Persistent or Recurrent Cancer of the Cervix | terminated | Phase 2 | — | Gynecologic Oncology GroupNETWORK | 2 | Apr 11, 2013 | clinicaltrials |
| NCT00332280 | Study to Evaluate the Clinical Benefit Response in Cancer Patients With Advanced Disease With AMT2003 Versus Placebo | terminated | Phase 2 / Phase 3 | 67 | Auron Healthcare GmbHINDUSTRY | 2 | Mar 20, 2013 | clinicaltrials |
| NCT00091195 | Depsipeptide (Romidepsin) in Treating Patients With Recurrent Ovarian Epithelial or Peritoneal Cavity Cancer | terminated | Phase 2 | 51 | National Cancer Institute (NCI)NIH | 1 | Mar 19, 2013 | clinicaltrials |
| NCT00002796 | Phase I-II Study of Fluorouracil in Combination With Phenylbutyrate in Advanced Colorectal Cancer | terminated | Phase 1 / Phase 2 | 46 | National Cancer Institute (NCI)NIH | 1 | Feb 1, 2013 | clinicaltrials |
| NCT00383487 | A Phase II Trial of Calcitriol and Naproxen in Patients With Recurrent Prostate Cancer | terminated | Phase 2 | 20 | Stanford UniversityOTHER | 1 | Jan 28, 2013 | clinicaltrials |
| NCT00523809 | Allogeneic Hematopoietic Stem Cell Transplantation With Bevacizumab for Advanced Solid Tumor | terminated | Phase 2 | 5 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 28, 2013 | clinicaltrials |
| NCT00005039 | Vaccine Therapy in Treating Patients With Advanced Adenocarcinoma of the Prostate (Prostate Cancer) | terminated | Phase 2 | 86 | National Cancer Institute (NCI)NIH | 1 | Jan 24, 2013 | clinicaltrials |
| NCT00042952 | Imatinib Mesylate in Treating Patients With Progressive, Refractory, or Recurrent Stage II or Stage III Testicular or Ovarian Cancer | terminated | Phase 2 | 32 | National Cancer Institute (NCI)NIH | 1 | Jan 17, 2013 | clinicaltrials |
| NCT00052585 | Gefitinib and Combination Chemotherapy in Treating Patients With Advanced or Recurrent Colorectal Cancer | terminated | Phase 2 | 50 | National Cancer Institute (NCI)NIH | 1 | Jan 16, 2013 | clinicaltrials |
| NCT00840450 | Imatinib Mesylate (Gleevec) and Paclitaxel in Recurrent Patients of Ovarian and Other Cancers of Mullerian Origin | terminated | Phase 2 | 14 | NYU Langone HealthOTHER | 1 | Nov 19, 2012 | clinicaltrials |
| NCT00714376 | Phase II Study of Docetaxel for Clinically Asymptomatic High Risk Prostate Cancer Patients(TAX1) | terminated | Phase 2 | 6 | CHU de Quebec-Universite LavalOTHER | 1 | Oct 31, 2012 | clinicaltrials |
| NCT00293371 | Docetaxel, Prednisone, and Vatalanib in Treating Patients With Advanced Prostate Cancer | terminated | Phase 1 / Phase 2 | 6 | University of California, San FranciscoOTHER | 1 | Oct 11, 2012 | clinicaltrials |
Data updated 23 days agoSource updated Sep 18, 2014source: clinicaltrials